eClinical Tech News

Moonlake Immunotherapeutics reported third-quarter 2025 results, with $380.5 million in cash and committed debt, extending the runway into the...

EyePoint Pharmaceuticals has fully enrolled its two Phase 3 wet AMD trials, LUGANO and LUCIA, with more than 900...

Centessa Pharmaceuticals reported positive initial Phase 2a results for ORX750, its oral OX2R agonist, across narcolepsy type 1, narcolepsy...

Upstream Bio reported positive phase 2 results for verekitug in chronic rhinosinusitis with nasal polyps and outlined a near-term...

Foghorn Therapeutics reported steady progress across its chromatin-targeting pipeline, keeping its SMARCA2 inhibitor FHD-909 on track in a Phase...

BioNTX closed 2025, signaling a step-change for the North Texas life sciences cluster: record member engagement approaching 200 organizations,...

Akari Therapeutics has outlined a 2026–2027 path to first-in-human testing of AKTX-101, a TROP2-directed antibody-drug conjugate featuring a novel...

Celularity has secured up to $12 million in new financing through two binding term sheets with a single accredited...

INVO Fertility has restructured its leadership to accelerate a clinic-led growth strategy, appointing Terah Krigsvold as chief financial officer...

XOMA Royalty Corporation has amended its long-standing collaboration with Takeda, returning a majority of its royalty interest in mezagitamab...